Said to be the first test for viral load measurement at point-of-care, the new technique delivers results within 70 minutes and thereby enables screening and treatment in a single visit.
For monitoring ART treatment failure, viral load testing is considered to be the benchmark. According to the World Health Organization (WHO), every person receiving ART should undergo a viral load test at 6 months and 12 months, and annually after that, if the individual is stable on ART.
Abbott Rapid Diagnostics , Infectious Disease-Emerging Markets vice-president Damian Halloran said: “Abbott is committed to delivering HIV diagnostic solutions that support the UNAIDS agenda and enable life-saving decisions that have a profound impact on people and society.
“The m-PIMA HIV-1/2 VL is an example of how Abbott is focused on delivering tools that empower healthcare providers and their patients where and when they need it most.”
m-PIMA HIV-1/2 VL expands the company’s portfolio of diagnostic solutions intended for HIV care across more than 120 countries, including all 55 African countries.
The quantitative nucleic acid amplification test is designed to measure the viral load of HIV-1 groups M/N and O, as well as HIV-2 in plasma samples.
It can be used on the portable m-PIMA platform and facilitates data point connectivity to support decentralised programme management.
Abbott’s HIV portfolio also includes a quantitative assay called RealTime HIV-1 developed to identify HIV-1 virus in blood spots or plasma samples obtained from infected individuals.
The in-vitro reverse transcription-polymerase chain reaction (RT-PCR) assay is intended to offer improved precision and accurate monitoring.